Induced Pluripotent Stem Cell-Derived Glial Enriched Progenitor Cells For The Treatment Of White Matter Stroke

Tech ID: 27229 / UC Case 2016-170-0

Summary

UCLA researchers in the Department of Neurology and the Department of Molecular, Cell & Developmental Biology have developed novel therapies for cerebral ischemic injuries, including white matter stroke, using glial-enriched progenitor cells.

Background

During the normal human aging process, the white matter regions of the brain suffer progressive damage related to both overt and clinically silent ischemia. The degree of white matter injuries closely correlates with abnormalities in cognition, balance, and gait, additionally carrying an increased risk of death. Progressive accumulation of cerebral white matter lesions is indicative of white matter stroke (WMS), which results in dementia over time or worsens symptoms when combined with Alzheimer’s disease. Currently, there is no therapy available for WMS.

The neural elements damaged in WMS include oligodendrocytes, oligodendrocyte progenitor cells (OPCs), astrocytes and axons. Astrocytes promote OPC survival and differentiation into the myelinating oligodendrocytes. Astrocyte- or glial-restricted progenitor cells have been shown to mitigate to injuries and promote stabilization of injured axons and growth of new connections in spinal cord injury transplant therapies. However, routine production of astrocyte- or glial-restricted progenitor cells from fetal-derived neural precursors is not possible for use in treatment in WMS because of the large volumes of cells that would be required for human therapy. In addition, production of glial-restricted or glial-enriched progenitors from embryonic stem cells or induced pluripotent stem cells is time-consuming and extremely inefficient.

Therefore, there is a need to develop novel therapies for cerebral ischemic injuries, including WMS. Moreover, there is a need for production of glial-enriched progenitor cells for use in cellular treatment for conditions requiring myelin repair and/or remyelination, such as WMS.

Innovation

Researchers at UCLA have developed novel therapies for treatment of cerebral ischemic injuries, including white matter stroke, that involve the administration of induced pluripotent glial-enriched progenitor cells. This new approach is able to repair neuronal networks disrupted by ischemic stroke. Experiments have shown increased myelination within the damaged white matter and reduced measures of reactive astrocytosis and inflammation post treatment.

Applications

  • Cerebral ischemic injury therapy
  • White matter stroke therapy
  • Production of glial-enriched progenitor cells

Advantages

Provides a renewable and scalable source of glial-enriched progenitors for therapeutics and research

State Of Development

Successfully tested in vivo in mouse models.

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20180271911 09/27/2018 2016-170
European Patent Office Published Application 3355898 08/08/2018 2016-170
Japan Published Application WO 2017/058819A 04/06/2017 2016-170
 

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Carmichael, Stanley T.

Other Information

Keywords

Ischemic injury, white matter stroke, therapeutic, stem cell, pluripotent, glial-enriched progenitor cell, myelination, research tool

Categorized As

Additional Technologies by these Inventors